
‘Stubborn' barriers prevent parents from vaccinating their children
The Royal College of Paediatrics and Child Health (RCPCH) formed a commission to look at declining vaccination rates and found that while some families are hesitant to vaccinate due to fears about the jabs, many face issues that could be resolved with more support.
It comes after Lord Vallance, the science minister, said people have forgotten that diseases such as measles can kill.
Uptake of vaccines in the UK has stalled over the last decade and is, in many cases, declining.
None of the routine childhood vaccinations have met the target for 95% coverage since 2021, meaning youngsters are at risk of catching illnesses such as measles, meningitis and whooping cough.
Key themes in the RCPCH study were that some people have difficulty booking appointments, especially ones that fit around work and childcare.
Parents also reported inconvenient clinic locations and the high cost of public transport to get to appointments.
There is also a lack of continuity of NHS care, with many parents seeing a different GP or clinician at each visit.
The absence of health visitors was also 'especially significant' as it is often individual family circumstances that influence vaccination decisions.
The report also noted a lack of reminders from GP surgeries about upcoming jabs, and a lack of digital records meaning parents and NHS staff could not easily see which jabs children had had.
Parents also feared being judged for raising concerns about vaccines or having beliefs in alternative medicine, the study found.
Researchers noted a growing disparity in vaccine uptake among some ethnic minority groups, socio-economically disadvantaged families and migrant communities.
They face language difficulties, digital exclusion, and challenges in navigating the NHS, the study found.
The report suggested that parents do not always have the information they want or need around vaccines, and that health professionals need more training on how to approach conversations about jabs.
Health professionals interviewed for the study also said there was a need for more pro-vaccine messages on social media, including using influencers to spread the message about why jabs are important.
'Public health campaigns should be countering misinformation in the places where parents/carers/young people are seeing it – on social media,' the report said.
' More needs to be done to share positive messages about vaccination and the benefits of getting vaccinated.'
The report also recommended making education on vaccinations 'a mandatory part of young people's personal health lessons, teaching young people about the public health benefits of vaccination, the science behind how vaccinations are developed and the serious health consequences of catching some of the vaccine-preventable diseases.'
RCPCH officer for health improvement, Dr Helen Stewart, said: 'Steady declines in vaccination rates in a wealthy country such as the United Kingdom is extremely concerning.
'Parents are often blamed for vaccine hesitancy, but the reality is that there are many who simply need better support and easier access to appointments.
'With the right guidance and access, they'd gladly protect their children with these essential vaccines.
'If we are ever to truly tackle low uptake, then we must first ensure that everyone who is willing to be vaccinated is able to do so quickly and easily.'
Alison Morton, chief executive of the Institute for Health Visitors, said: 'Whilst most parents get their children vaccinated without hesitation, the widening inequalities and decline in vaccine uptake rates are a national cause for concern.
'This timely report presents a compelling case to ensure babies and children are protected against serious diseases that were once feared by families and can cause so much unnecessary harm.'
Dr Julie Yates, deputy director for immunisations programmes at UKHSA, said: 'We know our colleagues in general practice and other services are working exceptionally hard to deliver our immunisation programmes and through their efforts they protect millions of children each year.
'However, we must not become complacent and UKHSA is committed to working with the NHS and partners to improve childhood vaccine uptake.
'Despite the challenges, it is also important to note that parents have high confidence in vaccinations with almost 90% agreeing vaccines are effective.
'The NHS England vaccination strategy is already working to improve the 'front door' to vaccination, ensuring more flexible appointment booking systems, making vaccines more widely available across locations, making access easier and ease of responding to the specific needs identified within each community.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Rhyl Journal
2 hours ago
- Rhyl Journal
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'


North Wales Chronicle
2 hours ago
- North Wales Chronicle
Record number of NHS operations given in private hospitals
Data from the Independent Healthcare Providers Network (IHPN) show that private hospitals delivered the equivalent of 2,859 NHS procedures every working day in April – an increase of over 60% compared to the same month in 2019. It said that almost one in five NHS operations in England are carried out in private hospitals and clinics. Overall, the independent sector is delivering 10% of all NHS planned care, up from 8% before the Covid-19 pandemic, the IHPN said. The IHPN also said that the number of referrals it had received has also reached a record high – with private providers receiving 7,162 referrals each working day in April. Official NHS data show that the waiting list for routine hospital treatment in England has fallen to its lowest level for two years. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. The Government has set out plans to send more patients for treatment in private hospitals to slash waiting lists. David Hare, chief executive of the IHPN, said: 'This latest data shows the independent sector's increasingly pivotal role in delivering frontline NHS care – delivering record levels of NHS care which will be instrumental in helping the Government to meet their key milestone to ensure 92% of patients are treated within 18 weeks by the end of this Parliament. 'While this is a clear sign of welcome progress in tackling NHS waiting lists, the sector is committed to building on this already impressive achievement and will be working with the Government to ensure the principles contained in the recent NHS and Independent Sector Partnership Agreement are fully embedded – enabling patients to have a greater choice over their care so they can get the treatment they need, when they need it.'


North Wales Chronicle
2 hours ago
- North Wales Chronicle
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'